SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cohance Lifesciences - Quaterly Results

28 May 2025 Evaluate
The sales figure stood at Rs. 3301.70 millions for the March 2025 quarter. The mentioned figure indicates a growth of about 30.54% as compared to Rs. 2529.30 millions during the year-ago period.A slender decline of -16.69% was recorded to Rs. 443.40  millions from Rs. 532.20 millions in the corresponding previous quarter.The company reported a degrowth in operating Profit to 738.10 millions from 903.90 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 3301.70 2529.30 30.54 10935.10 10513.50 4.01 10935.10 10513.50 4.01
Other Income 66.30 170.60 -61.14 539.80 566.10 -4.65 539.80 566.10 -4.65
PBIDT 738.10 903.90 -18.34 4165.50 4624.70 -9.93 4165.50 4624.70 -9.93
Interest 23.00 23.00 0.00 80.00 74.50 7.38 80.00 74.50 7.38
PBDT 715.10 880.90 -18.82 4085.50 4550.20 -10.21 4085.50 4550.20 -10.21
Depreciation 151.90 172.50 -11.94 572.00 546.00 4.76 572.00 546.00 4.76
PBT 563.20 708.40 -20.50 3513.50 4004.20 -12.25 3513.50 4004.20 -12.25
TAX 119.80 176.20 -32.01 796.40 1039.50 -23.39 796.40 1039.50 -23.39
Deferred Tax 93.30 -10.70 -971.96 -127.30 65.90 -293.17 -127.30 65.90 -293.17
PAT 443.40 532.20 -16.69 2717.10 2964.70 -8.35 2717.10 2964.70 -8.35
Equity 254.60 254.60 0.00 254.60 254.60 0.00 254.60 254.60 0.00
PBIDTM(%) 22.36 35.74 -37.45 38.09 43.99 -13.40 38.09 43.99 -13.40

Cohance Lifesciences Share Price

478.70 -9.60 (-1.97%)
11-May-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1282.15
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2249.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×